Document Mentions (4 shared documents)

EFTA00136746

2 mentions1 same-page

Page ?Same page

ing on `unsustainable drug prices' concludes — Hybrid hearing on `Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM * Tom Lantos Human

" According to Reuters, lawmakers "got few answers during the sometimes contentious 2-1/2 hour hearing." Acting Undersecretary of Defense for Policy James Anderson "said the military did not yet have details and would share plans as they are developed." The Washington Times <https://www.washingtontimes.cornine

EFTA00135712

2 mentions1 same-page

Page ?Same page

ing on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

euters, lawmakers EFTA00135747 "got few answers during the sometimes contentious 2-1/2 hour hearing." Acting Undersecretary of Defense for Policy James Anderson "said the military did not yet have details and would share plans as they are developed." The Washington Times (9/30, Toms, 492K) says "bipartisan

EFTA00148896

2 mentions1 same-page

Page ?Same page

ring on `unsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

According to Reuters, lawmakers "got few answers during the sometimes contentious 2-1/2 hour hearing." Acting Undersecretary of Defense for Policy James Anderson "said the military did not yet have details and would share plans as they are developed." The Washington Times (9/30, Toms, 492K) says "bipartisan